Overall, results from this study contribute to our understanding of MYD88-driven lymphomas, suggests a possible clinical implication for those individuals that harbor both a MYD88 mutation and a loss of TNFAIP3, and also provides us with a useful model to study novel therapeutic strategies in patients who harbor these genetic variants. This evidence concerns the gene MYD88 and lymphoma.